Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver
disease company developing novel bile acid modulators, today
announced late-breaker acceptances by the American Association for
the Study of Liver Diseases (AASLD) for the Phase 3 PEDFIC 1 trial
and PEDFIC 2 long-term extension trial. There will be an oral
presentation of the results from PEDFIC 1, the global Phase 3
clinical trial evaluating the efficacy and safety of odevixibat in
children with progressive familial intrahepatic cholestasis (PFIC)
in the late-breaker session. PEDFIC 2 is an open-label Phase 3
extension study of the long-term efficacy and safety of odevixibat
in children with PFIC, and interim results will be presented as a
late-breaker poster. In addition, data on novel bile acid modulator
approaches and new product candidate A3907 have also been accepted
for poster presentations. The AASLD The Liver Meeting Digital
Experience™ (TLMdX) is being held November 13-16.
“PEDFIC 1 achieved very high statistical significance on both
the U.S. and EU primary endpoints and we are eager to share the
full results from the PEDFIC program to date. Odevixibat sustained
reductions in bile acids and pruritus, improved growth parameters,
and was well tolerated with very low incidence of diarrhea across a
wide range of PFIC patients,” said Ron Cooper, President and Chief
Executive Officer of Albireo. “Our scientific leadership and
pipeline execution will also shine with exciting data introducing
multiple new bile acid modulator approaches focusing on our novel
compound A3907 in adult liver diseases.”
Abstracts are now available on the AASLD website. Details of the
late-breaking abstracts will be presented in November and published
in the December issue of HEPATOLOGY:
Presentation #L04:
Efficacy and Safety of Odevixibat, an Ileal Bile Acid Transporter
Inhibitor, in Children with Progressive Familial Intrahepatic
Cholestasis Types 1 and 2: Results from PEDFIC 1, a Randomized,
Double-Blind, Placebo-Controlled Phase 3 Trial
Session:
Late-breaking Oral Abstract Session 1 with presentation by lead
author Richard J. Thompson, M.D., Ph.D., Professor of Molecular
Hepatology at King's College London and principal investigator of
the studyDate &
Time: Sunday, Nov. 15, 5:30 p.m. EST
Poster
#LP19: Long-term Efficacy and Safety of
Odevixibat, an Ileal Bile Acid Transporter Inhibitor, in Children
with Progressive Familial Intrahepatic Cholestasis: Interim Results
from PEDFIC 2, an Open-label Phase 3 Trial
Session:
Late-breaking Abstract Posters
Abstracts accepted earlier in the month were published in the
October issue of HEPATOLOGY and included one abstract selected by
TLMdX as a Poster of Distinction for being in the top 10 percent of
scored poster abstracts.
Poster #348:
Discovery and Characterization of Novel Bile Acid Transporter
Inhibitors with Potential for Treatment of Liver Diseases
Session: Biliary
Transport and Metabolism
Poster of
Distinction #509: A3907,
a Novel Inhibitor of Bile Acid Transport in the Intestine and
Kidney, Improves Markers of Metabolic and Hepatic Pathology, and
Reduces Nonalcoholic Fatty Liver Disease Activity Score and
Fibrosis Stage in a Diet-induced and Biopsy-confirmed Mouse Model
of Nonalcoholic Steatohepatitis
Session:
Experimental NAFLD and NASH
About OdevixibatOdevixibat is an
investigational product candidate being developed to treat rare
pediatric cholestatic liver diseases, including progressive
familial intrahepatic cholestasis (PFIC), biliary atresia and
Alagille syndrome. A highly potent, once-daily, non-systemic ileal
bile acid transport inhibitor (IBATi), odevixibat acts locally in
the small intestine. Odevixibat does not require refrigeration
and can be taken as a capsule for older children, or opened and
sprinkled onto food, which are factors of key importance for
adherence in a pediatric patient population. Albireo conducted the
largest ever global Phase 3 trial in PFIC1 and PFIC2. The PEDFIC 1
trial evaluated odevixibat 40 µg/kg/day or 120 µg/kg/day or placebo
in 62 patients, ages 6 months to 15.9 years. Positive results from
the trial were announced on September 8, 2020: News Release –
Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat
in PFIC. Odevixibat is currently being evaluated in the ongoing
PEDFIC 2 open-label trial (NCT03659916) and the BOLD Phase 3 trial
in patients with biliary atresia (NCT04336722). Initiation of a
pivotal Phase 3 trial of odevixibat for Alagille syndrome is also
anticipated by the end of 2020.
Odevixibat has received fast track, rare pediatric disease and
orphan drug designations in the United States. In
addition, the FDA has granted orphan drug designation to
odevixibat for the treatment of Alagille syndrome, biliary atresia
and primary biliary cholangitis. The EMA has granted
odevixibat orphan designation, as well as access to the PRIority
MEdicines (PRIME) scheme for the treatment of PFIC. Its Pediatric
Committee has agreed to Albireo’s odevixibat Pediatric
Investigation Plan for PFIC and biliary atresia. EMA has also
granted orphan designation to odevixibat for the treatment of
Alagille syndrome, biliary atresia and primary biliary cholangitis.
Odevixibat has the potential to become the first approved drug
treatment for patients with PFIC. The Company intends to complete
regulatory filings in the EU and U.S. for odevixibat in PFIC no
later than early 2021, in anticipation of potential regulatory
approval, issuance of a rare pediatric disease priority review
voucher and launch in the second half of 2021.
About AlbireoAlbireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat rare pediatric and adult liver diseases,
and other adult liver diseases and disorders. Albireo’s lead
product candidate, odevixibat, is being developed to treat rare
pediatric cholestatic liver diseases and is in Phase 3 development
in progressive familial intrahepatic cholestasis (PFIC) and biliary
atresia, with a third Phase 3 trial being planned in Alagille
syndrome. The Company expects to complete IND-enabling studies for
new preclinical candidate A3907 this year. Albireo was spun out
from AstraZeneca in 2008 and is headquartered in Boston,
Massachusetts, with its key operating subsidiary
in Gothenburg, Sweden. The Boston Business
Journal named Albireo one of the 2020 Best Places to Work
in Massachusetts for the second consecutive year. For more
information on Albireo, please
visit www.albireopharma.com.Forward-Looking
Statements This press release includes “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include
statements, other than statements of historical fact, regarding,
among other things: the plans for, or progress, scope, cost,
initiation, duration, enrollment, results or timing for
availability of results of, development of odevixibat or any other
Albireo product candidate or program, including regarding
expectations regarding the impact of COVID-19 on our business and
our ability to adapt our approach as appropriate; the Phase 3
clinical program for odevixibat in patients with PFIC, the pivotal
trial for odevixibat in biliary atresia (BOLD), and the planned
pivotal trial for odevixibat in Alagille syndrome; the target
indication(s) for development or approval, the size, design,
population, location, conduct, cost, objective, enrollment,
duration or endpoints of any clinical trial, or the timing for
initiation or completion of or availability or reporting of results
from any clinical trial, including the long-term open-label
extension study for odevixibat in PFIC, the pivotal trial for
odevixibat in biliary atresia, the planned pivotal trial for
odevixibat in Alagille syndrome; the potential approval and
commercialization of odevixibat; discussions with the FDA or EMA
regarding our programs; the potential benefits or competitive
position of odevixibat, elobixibat, or any other Albireo product
candidate or program or the commercial opportunity in any target
indication; the potential effects of odevixibat of the treatment of
PFIC patients and its potential to improve the current standard of
care; the potential benefits of an orphan drug designation; the
potential issuance of a rare pediatric disease priority review
voucher; or Albireo’s plans, expectations or future operations,
financial position, revenues, costs or expenses. Albireo often
uses words such as “anticipates,” “believes,” “plans,” “expects,”
“projects,” “future,” “intends,” “may,” “will,” “should,” “could,”
“estimates,” “predicts,” “potential,” “planned,” “continue,”
“guidance,” and similar expressions to identify forward-looking
statements. Actual results, performance or experience may differ
materially from those expressed or implied by any forward-looking
statement as a result of various risks, uncertainties and other
factors, including, but not limited to: negative impacts of the
COVID-19 pandemic, including on manufacturing, supply, conduct or
initiation of clinical trials, or other aspects of our business;
whether favorable findings from clinical trials of odevixibat to
date, including findings in indications other than PFIC, will be
predictive of results from other clinical trials of odevixibat;
whether either or both of the FDA and EMA will determine
that the primary endpoint for their respective evaluations and
treatment duration of the double-blind Phase 3 trial in patients
with PFIC are sufficient to support approval of odevixibat
in the United States or the European Union, to treat
PFIC, a symptom of PFIC, a specific PFIC subtype(s) or otherwise;
the outcome and interpretation by regulatory authorities of the
ongoing third-party study pooling and analyzing of long-term PFIC
patient data; the timing for initiation or completion of, or for
availability of data from, clinical trials of odevixibat, including
the pivotal program in biliary atresia or the planned pivotal
program in Alagille syndrome, and the outcomes of such trials;
Albireo’s ability to obtain coverage, pricing or reimbursement for
approved products in the United States or European
Union; delays or other challenges in the recruitment of patients
for, or the conduct of, company’s clinical trials; and Albireo’s
critical accounting policies. These and other risks and
uncertainties that Albireo faces are described in greater detail
under the heading “Risk Factors” in Albireo’s most recent Annual
Report on Form 10-K or in subsequent filings that it makes with
the Securities and Exchange Commission. As a result of risks
and uncertainties that Albireo faces, the results or events
indicated by any forward-looking statement may not occur. Albireo
cautions you not to place undue reliance on any forward-looking
statement. In addition, any forward-looking statement in this press
release represents Albireo’s views only as of the date of this
press release and should not be relied upon as representing its
views as of any subsequent date. Albireo disclaims any obligation
to update any forward-looking statement, except as required by
applicable law.
Media
Contacts: Colleen
Alabiso, 857-356-3905, colleen.alabiso@albireopharma.comHeather
Anderson, 6 Degrees, 919-827-5539, handerson@6degreespr.com
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC., 857-272-6177
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024